近距离放疗联合方案与根治性前列腺切除在高危局限前列腺癌中生存相似
该回顾性队列研究分析美国国家癌症数据库42,765例高危临床局限前列腺癌患者,采用逆概率加权和时依Cox模型比较三种治疗方式的生存。结果显示根治性前列腺切除与体外放疗联合近距离放疗(±雄激素剥夺)生存无统计学差异(HR 1.17,95%CI 0.88–1.55),而体外放疗联合雄激素剥夺死亡率更高(HR 1.53,95%CI 1.22–1.92)。
要点
- 高危局限前列腺癌中,根治性切除与体外放疗联合近距离放疗生存无显著差异。
- 体外放疗联合雄激素剥夺较根治性切除死亡率显著更高(HR 1.53)。
- 即使体外放疗剂量≥7920 cGy,联合雄激素剥夺的死亡率仍显著更高(HR 1.33)。
核心结论
- 综合调整肿瘤预后、合并症及社会经济因素后,根治性前列腺切除与体外放疗联合近距离放疗(±雄激素剥夺)生存无统计学差异。
- 体外放疗联合雄激素剥夺与更低的生存相关。
研究设计与样本
- 回顾性分析美国国家癌症数据库(National Cancer Database)中高危、临床局限且预后数据完整的前列腺癌患者。
- 共纳入42,765例患者,接受根治性前列腺切除、体外放疗联合雄激素剥夺或体外放疗联合近距离放疗(±雄激素剥夺)。
- 采用逆概率治疗加权调整组间协变量失衡,并使用加权时依Cox比例风险模型估计治疗对生存的影响。
- 基于前列腺特异性抗原、Gleason评分和临床T分期构建病理淋巴结状态预测模型,并重复加权和Cox分析。
主要发现
- 根治性前列腺切除与体外放疗联合近距离放疗(±雄激素剥夺)生存无统计学显著差异(HR 1.17;95%CI 0.88–1.55)。
- 体外放疗联合雄激素剥夺较根治性前列腺切除死亡率更高(HR 1.53;95%CI 1.22–1.92)。
- 按预测病理淋巴结状态调整后结果无统计学差异。
- 敏感性分析显示体外放疗联合雄激素剥夺剂量≥7920 cGy可缩小差异,但死亡率仍显著更高(HR 1.33;95%CI 1.05–1.68)。
临床怎么用
- 在高危局限前列腺癌治疗决策中,根治性切除与体外放疗联合近距离放疗(±雄激素剥夺)可作为生存相似的选项。
- 体外放疗联合雄激素剥夺方案与更低的生存相关,选择时需权衡。
局限性
- 无随机对照试验,为回顾性数据库分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose There are no randomized trials to guide treatment decisions between radiotherapeutic and surgical options for patients with high-risk localized prostate cancer. Comparative studies have been limited by their ability to match patients on the basis of pretreatment prognostic variables and to adjust for the cancer-related, medical, and socioeconomic differences between patients who choose radiotherapeutic or surgical approaches. Methods We analyzed the outcome of all patients in the National Cancer Database with high-risk, clinically localized prostate cancer with complete prognostic data who were treated with either radical prostatectomy (RP), external beam radiotherapy (EBRT) combined with androgen deprivation (AD), or EBRT plus brachytherapy with or without AD. Inverse probability of treatment weighting was used to adjust for covariable imbalance among treatment groups. The weighted time-dependent Cox proportional hazards model was then used to estimate the effects of treatment groups on survival, accounting for differential treatment initiation times. A predictive model of pathologic nodal (pLN) status was built using prostate-specific antigen level, Gleason score, and clinical T stage; predicted pLN status was used to repeat the inverse probability of treatment weighting and time-dependent Cox proportional hazards model. Results A total of 42,765 patients were analyzed. There was no statistically significant difference in survival between RP and EBRT plus brachytherapy with or without AD (hazard ratio [HR], 1.17; 95% CI, 0.88 to 1.55). However, EBRT plus AD was associated with higher mortality than RP (HR, 1.53; 95% CI, 1.22 to 1.92). Adjustment for predicted pLN status did not yield statistically different results. A sensitivity analysis showed that EBRT plus AD ≥ 7920 cGy narrowed the difference, but a significantly higher mortality remained (HR, 1.33; 95% CI, 1.05 to 1.68). Conclusion After comprehensively adjusting for imbalances in prostate cancer prognostic factors, other medical conditions, and socioeconomic factors, this analysis showed no statistical difference in survival between patients treated with RP versus EBRT plus brachytherapy with or without AD. EBRT plus AD was associated with lower survival.
引用
- Ennis RD, Hu L, Ryemon SN, et al. Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer. J Clin Oncol. 2018. PMID: 29489433. doi:10.1200/JCO.2017.75.9134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。